FilingSEC EDGAR8-K
PMGC Holdings Expands AI Drug Discovery Program and Increases Authorized Capital
· SEC accepted
StageAgreement Amendment and Capital Increase
Filing content
Subsidiary NorthStrive Biosciences amended its license agreement with Yuva Biosciences to expand its AI drug discovery program, while the company increased its authorized capital to 1.5 billion shares.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…